Clinical InvestigationSuppressed soluble Fms–like tyrosine kinase-1 production aggravates atherosclerosis in chronic kidney disease
Under an Elsevier user license
open archive
KEYWORDS
atherosclerosis
chronic kidney disease
placental growth factor
soluble fms-like tyrosine kinase-1
Cited by (0)
YS received lecture fees from Merck, Takeda Pharmaceutical Company, Novartis Pharma KK, Daiichi Sankyo Company, Mitsubishi Tanabe Pharma Corporation, Pfizer Japan, Otsuka Pharmaceutical, and research fundings from Merck, Takeda Pharmaceutical Company Limited, Novartis Pharma KK, Daiichi Sankyo Company, Mitsubishi Tanabe Pharma Corporation, Pfizer Japan, Otsuka Pharmaceutical, Astellas Pharma, Baxter, AstraZeneca KK, Shionogi. YS and SS also belong to the endowed department (the Department of Regulatory Medicine of Blood Pressure) sponsored by Merck.
- 3
These authors contributed equally to this work.
- 4
Current address: Department of Nephrology, Fukui University, Japan.
Copyright © 2014 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.